Literature DB >> 18393290

Interactions of pluronic block copolymers on P-gp efflux activity: experience with HIV-1 protease inhibitors.

Naveed Shaik1, Guoyu Pan, William F Elmquist.   

Abstract

The objective was to examine the influence of Pluronic block-copolymers on the interaction between the drug efflux transporter, P-glycoprotein and HIV-1 protease inhibitors (PIs). The ATPase assay determined the effect of various Pluronics on PI-stimulated P-gp ATPase activity. Cellular accumulation studies were conducted using MDCKII and LLC-PK1 cells transfected with human MDR1 to assess Pluronic modulation of PI efflux. Pluronic P85 inhibited both basal and nelfinavir-stimulated P-gp ATPase activity, while Pluronic F127 had no effect. In cell accumulation studies, Pluronic P85 restored the accumulation of nelfinavir in MDCKII-MDR1 cells while Pluronic F127 and F88 had no effect. Pluronic P85 increased saquinavir accumulation in wild-type and MDR1-transfected cells in both the MDCKII and LLC-PK1 cell models, suggesting inhibition of multiple transporters, including MRPs. In conclusion, this study provides evidence that a block-copolymer, Pluronic P85, effectively inhibits the interaction of P-gp with nelfinavir and saquinavir. These data indicate that effective inhibition of HIV-1 PI efflux by Pluronic P85 may influence the distribution of antiretroviral agents to sites protected by efflux mechanisms, such as the blood-brain barrier, and possibly increase the brain exposure of these drugs resulting in suppression of viral replication and reduction in the incidence of drug resistant mutants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393290      PMCID: PMC5096432          DOI: 10.1002/jps.21372

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  55 in total

1.  Persistence of HIV-1 variants with multiple protease inhibitor (PI)-resistance mutations in the absence of PI therapy can be explained by compensatory fixation.

Authors:  Noortje M van Maarseveen; Annemarie M J Wensing; Dorien de Jong; Maaike Taconis; Jan C C Borleffs; Charles A B Boucher; Monique Nijhuis
Journal:  J Infect Dis       Date:  2006-12-29       Impact factor: 5.226

2.  Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers.

Authors:  E V Batrakova; S Li; D W Miller; A V Kabanov
Journal:  Pharm Res       Date:  1999-09       Impact factor: 4.200

3.  P-glycoprotein and mutlidrug resistance-associated proteins limit the brain uptake of saquinavir in mice.

Authors:  Seonghee Park; Patrick J Sinko
Journal:  J Pharmacol Exp Ther       Date:  2004-11-04       Impact factor: 4.030

4.  Interaction of imatinib mesilate with human P-glycoprotein.

Authors:  Akinobu Hamada; Hideto Miyano; Hiroshi Watanabe; Hideyuki Saito
Journal:  J Pharmacol Exp Ther       Date:  2003-09-15       Impact factor: 4.030

5.  Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization.

Authors:  E V Batrakova; S Li; S V Vinogradov; V Y Alakhov; D W Miller; A V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

6.  Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells.

Authors:  Elena V Batrakova; Shu Li; Valery Yu Alakhov; Donald W Miller; Alexander V Kabanov
Journal:  J Pharmacol Exp Ther       Date:  2003-02       Impact factor: 4.030

7.  Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment.

Authors:  Theresa K Smit; Bruce J Brew; Wallace Tourtellotte; Susan Morgello; Benjamin B Gelman; Nitin K Saksena
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1).

Authors:  Y Tanigawara; N Okamura; M Hirai; M Yasuhara; K Ueda; N Kioka; T Komano; R Hori
Journal:  J Pharmacol Exp Ther       Date:  1992-11       Impact factor: 4.030

9.  Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-Polycaprolactone amphiphilic diblock copolymers.

Authors:  Jason Zastre; John Jackson; Helen Burt
Journal:  Pharm Res       Date:  2004-08       Impact factor: 4.200

10.  Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats.

Authors:  Hongjian Zhang; Ming Yao; Richard A Morrison; Saeho Chong
Journal:  Arch Pharm Res       Date:  2003-09       Impact factor: 4.946

View more
  18 in total

1.  Cardamonin, a natural chalcone, reduces 5-fluorouracil resistance of gastric cancer cells through targeting Wnt/β-catenin signal pathway.

Authors:  Gaochao Hou; Xiang Yuan; Yi Li; Gaoyu Hou; Xianli Liu
Journal:  Invest New Drugs       Date:  2019-05-17       Impact factor: 3.850

2.  A folate receptor-targeting nanoparticle minimizes drug resistance in a human cancer model.

Authors:  Xu Wang; Jun Li; Yuxiang Wang; Lydia Koenig; Ada Gjyrezi; Paraskevi Giannakakou; Edwin H Shin; Mourad Tighiouart; Zhuo Georgia Chen; Shuming Nie; Dong M Shin
Journal:  ACS Nano       Date:  2011-07-11       Impact factor: 15.881

Review 3.  Recent developments of nanotherapeutics for targeted and long-acting, combination HIV chemotherapy.

Authors:  Yu Gao; John C Kraft; Danni Yu; Rodney J Y Ho
Journal:  Eur J Pharm Biopharm       Date:  2018-04-17       Impact factor: 5.571

Review 4.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

5.  Substrate-dependent breast cancer resistance protein (Bcrp1/Abcg2)-mediated interactions: consideration of multiple binding sites in in vitro assay design.

Authors:  Nagdeep Giri; Sagar Agarwal; Naveed Shaik; Guoyu Pan; Ying Chen; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2008-12-04       Impact factor: 3.922

Review 6.  Progress in antiretroviral drug delivery using nanotechnology.

Authors:  Rama Mallipeddi; Lisa Cencia Rohan
Journal:  Int J Nanomedicine       Date:  2010-08-09

7.  Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: cell accumulation and equilibrium dialysis studies.

Authors:  Naveed Shaik; Nagdeep Giri; William F Elmquist
Journal:  J Pharm Sci       Date:  2009-11       Impact factor: 3.534

Review 8.  NanoART, neuroAIDS and CNS drug delivery.

Authors:  Ari Nowacek; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2009-07       Impact factor: 5.307

Review 9.  Anti-HIV-1 nanotherapeutics: promises and challenges for the future.

Authors:  Supriya D Mahajan; Ravikumar Aalinkeel; Wing-Cheung Law; Jessica L Reynolds; Bindukumar B Nair; Donald E Sykes; Ken-Tye Yong; Indrajit Roy; Paras N Prasad; Stanley A Schwartz
Journal:  Int J Nanomedicine       Date:  2012-10-05

Review 10.  Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: Using nanoparticles to overcome multidrug resistance.

Authors:  Kushal Vanamala; Katyayani Tatiparti; Ketki Bhise; Samaresh Sau; Marc H Scheetz; Michael J Rybak; David Andes; Arun K Iyer
Journal:  Drug Discov Today       Date:  2020-10-20       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.